ENHANCING THE ANTI-CANCER IMMUNE RESPONSE BY COMBINING RADIOTHERAPY AND IMMUNOTHERAPY
Grant number: 1122347 | Funding period: 2017 - 2020
Lung cancer is the biggest cause of cancer related death in Australia. Recently, immune therapies have shown promise by unlocking the body’s own defenses to fight against lung cancer. I aim to maximise the effect of the anti-PD-1 immune therapy by ‘kick-starting’ the immune response with high-precision stereotactic ablative body radiotherapy (SABR). By completing clinical trials and biological research into the combination of therapies I hope to improve outcomes for patients with lung cancer.
Related publications (3)
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
Shankar Siva, Cristian Udovicich, Ben Tran, Homi Zargar, Declan G Murphy, Michael S Hofman
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly being established as arguably the leading ..
Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in non-small cell lung cancer
Aidan Joseph Cole, Nicholas Hardcastle, Guy-Anne Turgeon, Roshini Thomas, Louis B Irving, Barton R Jennings, David Ball, Tomas Kron, Daniel P Steinfort, Shankar Siva
Objectives: Patients suitable for radical chemoradiotherapy for lung cancer routinely have radiotherapy (planning) volumes based o..